Merck & Co., Inc. (MRK) — closed signal from September 1, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on November 30, 2025.
Predicted vs. what happened
What happened
Reached its target in 73 days.
The thesis — published September 1, 2025
Merck looks like a steady, larger company with solid profits and a clear path to grow. A recent report scored it 93% on a well-known value-and-growth checklist inspired by investor Peter Lynch, meaning the stock offers a good mix of fair price and growth. Buying interest is improving without getting overheated. Big drug makers can help steady a portfolio, while new medicines and execution can lift results over time.
Primary drivers
- High score on a respected value-and-growth checklist, signaling balance
- Reliable profits and a dividend that cushions market swings for investors
- Buying interest is rising without signs of overheating in the stock price
- Multiple drug prospects and solid delivery create room to grow over time
How it played out
MRK: target reached in 73 days
Lyra published MRK at 82.59 on 2025-09-01 with a short-term thesis for 12% growth toward 90.82. The thesis pointed to a 93% value-and-growth checklist score, reliable profits, a dividend, rising buying interest without overheating, and multiple drug prospects with solid delivery.
Inside the 2025-09-01 to 2025-11-30 window, MRK reached the target in 73 days. The stock peaked at 104.94 on 2025-11-25, a 27.1% gain, and ended the window at 103.94. The published thesis played out. It did more than reach the target.
What happened during the window
On 2025-10-30, Merck reported third-quarter 2025 results, and Investors.com reported sales of $17.28 billion and adjusted earnings per share of $2.58. On 2025-11-14, Investopedia reported that Merck agreed to buy Cidara Therapeutics in an all-cash deal worth $9.2 billion.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.